{"prompt": "['5.2.1', 'Adverse Events', 'According to the ICH guideline for Good Clinical Practice, an adverse event is any untoward', 'medical occurrence in a clinical investigation subject administered a pharmaceutical product,', 'regardless of causal attribution. An adverse event can therefore be any of the following:', 'Any unfavourable and unintended sign (including an abnormal laboratory finding),', 'symptom, or disease temporally associated with the use of a medicinal product, whether', 'or not considered related to the medicinal product', 'Any new disease or exacerbation of an existing disease (a worsening in the character,', 'frequency, or severity of a known condition), except as described in Section 5.3.5.10', 'Recurrence of an intermittent medical condition (e.g., headache) not present at baseline', 'Any deterioration in a laboratory value or other clinical test (e.g., electrocardiogram', '[ECG], X-ray) that is associated with symptoms or leads to a change in study treatment', 'or concomitant treatment or discontinuation from study drug', 'Adverse events that are related to a protocol-mandated intervention, including those that', 'occur prior to assignment of study treatment (e.g., screening invasive procedures such', 'as biopsies).', 'Bleeds considered as serious adverse events should be reported on the appropriate adverse', \"event eCRF page, regardless of whether the bleeds are consistent with the patient's pre-\", \"study disease state (the bleed will also be recorded in the patient's bleed/medication\", \"records). New, non-serious bleeds consistent with patients' pre-study disease state will not\", 'be considered adverse events and will not be recorded on the eCRF but will be captured in', \"the patient's bleed/medication records.\", '5.2.2', 'Serious Adverse Events (Immediately Reportable to the Sponsor)', 'A serious adverse event is any adverse event that meets any of the following criteria:', 'Is fatal (i.e., the adverse event actually causes or leads to death)', 'Is life threatening (i.e., the adverse event, in the view of the investigator, places the', 'patient at immediate risk of death)', 'This does not include any adverse event that had it occurred in a more severe form or', 'was allowed to continue might have caused death.', 'Requires or prolongs inpatient hospitalization (see Section 5.3.5.11)', 'Results in persistent or significant disability/incapacity (i.e., the adverse event results in', \"substantial disruption of the patient's ability to conduct normal life functions)\", 'Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to', 'study drug', \"Is a significant medical event in the investigator's judgment (e.g., may jeopardize the\", 'patient or may require medical/surgical intervention to prevent one of the outcomes listed', 'above).', 'The terms \"severe\" and \"serious\" are not synonymous. Severity refers to the intensity of an', 'adverse event (e.g., rated as Grade 1-4, according to the World Health Organization [WHO]', 'toxicity grading scale for determining the severity of adverse events; see Section 5.3.3); the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '131 / Protocol MO39129, Version 3']['event itself may be of relatively minor medical significance (such as Grade 3 headache', 'without any further findings).', 'Severity and seriousness need to be independently assessed for each adverse event', 'recorded on the eCRF.', 'Serious adverse events are required to be reported by the investigator to the Sponsor', 'immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for', 'reporting instructions).', '5.2.3', 'Adverse Events of Special Interest (Immediately Reportable to the', 'Sponsor)', 'Adverse events of special interest are required to be reported by the investigator to the', 'Sponsor immediately (i.e., no more than 24 hours after learning of the event; see', 'Section 5.4.2 for reporting instructions). Adverse events of special interest for this study', 'include the following:', 'Cases of potential drug-induced liver injury that include an elevated ALT or AST in', \"combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's law\", '(see Section 5.3.5.7)', 'Suspected transmission of an infectious agent by the study drug, as defined below', 'Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible', 'spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious', 'agent. A transmission of an infectious agent may be suspected from clinical symptoms or', 'laboratory findings that indicate an infection in a patient exposed to a medicinal product.', 'This term applies only when a contamination of the study drug is suspected.', 'Systemic hypersensitivity reactions and anaphylactic and anaphylactoid reactions (see', \"Sampson's Criteria in Appendix 4)\", 'Thromboembolic events', 'Microangiopathic hemolytic anemia or TMA (e.g. hemolytic uremic syndrome).', '5.3', 'METHODS AND TIMING FOR CAPTURING AND ASSESSING', 'SAFETY PARAMETERS', 'The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for', 'definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in', 'accordance with instructions provided in this section and in Sections 0-5.6.', 'For each adverse event recorded on the Adverse Event eCRF, the investigator will make an', 'assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see', 'Section 5.3.3), and causality (see Section 0).', '5.3.1', 'Adverse Event Reporting Period', 'Investigators will seek information on adverse events at each patient contact. All adverse', 'events, whether reported by the patient or noted by study personnel, will be recorded in the', \"patient's medical record and on the Adverse Event eCRF.\", 'Emicizumab - F. Hoffmann-La Roche Ltd', '132 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}